cinacalcet

Known as: (R)-alpha-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine, CNC, N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
BACKGROUND Disorders of mineral metabolism, including secondary hyperparathyroidism, are thought to contribute to extraskeletal… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND This prospective, randomized, controlled trial compared the progression of vascular and cardiac valve calcification in… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND The use and effectiveness of cinacalcet in 'real-world' clinical practice was investigated in a pan-European… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND AND OBJECTIVES Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower parathyroid hormone… (More)
Is this relevant?
2006
2006
Cinacalcet, a calcimimetic, was evaluated in persistent hyperparathyroidism after kidney transplantation (Tx). Ten kidney… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Management of secondary hyperparathyroidism is challenging with traditional therapy. The calcimimetic cinacalcet HCl acts on the… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Secondary hyperparathyroidism (HPT) and abnormal mineral metabolism are thought to play an important role in bone and… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/DOQItrade mark) has established… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Calcimimetic compounds, which activate the parathyroid cell Ca(2+) receptor (CaR) and inhibit parathyroid hormone (PTH) secretion… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Calcimimetics increase the sensitivity of the calcium-sensing receptor (CaR) to circulating serum calcium, reducing the secretion… (More)
Is this relevant?